NEW YORK, June 15, 2026, 06:48 EDT
- Palantir settled at $127.99 in the last session, off 2.36%. Early Monday quotes are holding around that same level.
- Palantir is set to report Q2 results. The company sees revenue between $1.797 billion and $1.801 billion.
- Bulls point to strong U.S. AI demand, but bears focus on valuation concerns, governance issues, and the company’s exposure to public sector contracts.
Palantir Technologies Inc. heads into the week with the same doubts trailing it. The company is putting up fast growth, but PLTR trades like mistakes aren’t allowed. Shares closed at $127.99 on Nasdaq Friday, down 2.36%. Its price-to-earnings ratio early Monday was around 144. That’s high, and it means the stock is priced for a lot of future success. After hours Friday, MarketWatch had it quoted at $128.22, barely changed. MarketWatch
Palantir is seen as an AI growth stock. Its shares tend to move on changes in revenue, profit outlook, or the market’s willingness to pay up for its earnings. The stock has dropped in the past when investors got skittish, sold on doubt, or fretted over future cash. Growth isn’t the issue at the moment. The debate is whether Palantir is worth its current price.
Palantir bulls still have some numbers in their corner. Q1 revenue hit $1.633 billion, up 85% year-over-year. U.S. revenue jumped 104%, with U.S. commercial revenue up 133%. For full-year 2026, Palantir is guiding for revenue between $7.650 billion and $7.662 billion. CEO Alex Karp pointed to a “Rule of 40 score” at 145%—the sum of revenue growth and adjusted operating margin, where 40% is usually the benchmark for software firms. Karp said the outlook hike is from “our confidence in an accelerating U.S. market.” SEC
Bears are speaking up again. Palantir investors voted down proposals tied to due diligence, a human-rights review, and political spending, per a June 9 SEC filing. Barron’s noted that if insider votes are left out, 56% of outside shareholders supported the human-rights review. Reuters said the UK government is reviewing Palantir’s £330 million NHS deal, with a possible break in 2027 on the table. Palantir relies on public contracts. U.S. government revenue for the first quarter was $687 million, a jump of 84% from a year earlier. SEC
Palantir analyst calls are mixed. MarketBeat tracks 31 analysts on the stock, average 12-month target sitting at $192.76. Price targets start at $90 and top out at $255. These are guesses at future moves for Palantir, not guarantees. Bulls point to the AI Platform, work with the federal government, and commercial sales in the U.S. after shares pulled back. Bears say too much growth is already in the price, and warn about contract risks or governance problems. MarketBeat
Palantir changes hands at about 144 times earnings—still expensive. The story keeps moving, but the stock carries a big premium. Q2 results are next up. The street is watching for revenue in the $1.797 billion to $1.801 billion range, steady U.S. commercial demand, and firm margins as contract headlines and political attention stick around. SEC
